What is Rezubio?
Rezubio is a biotechnology firm based in China, focused on the development of innovative membrane-anchored medicines. These therapies are engineered to deliver highly targeted treatments, aiming to minimize systemic exposure and enhance therapeutic efficacy. The company's approach represents a significant advancement in precision medicine.
How much funding has Rezubio raised?
Rezubio has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2025): $20M with participation from FreeS Fund
Key Investors in Rezubio
FreeS Fund
FREES FUND is a venture capital firm based in Beijing, China, specializing in early-stage and early growth-stage startups within the technology and innovation sectors.
What's next for Rezubio?
With this major enterprise-level funding, Rezubio is poised for significant expansion and further research and development. The strategic investment will likely fuel the advancement of its pipeline, potentially leading to clinical trials and eventual market entry. This capital infusion positions Rezubio to further solidify its standing in the competitive global biotechnology landscape.
See full Rezubio company page
